Xenitra Locks $30M Danone Deal, Boosts B2B Reach with Rockcheck
Xenitra Limited has secured a $30 million AUD sales agreement for Danone products with Rockcheck Group and established its Australian subsidiary as an authorised supplier, marking a major step in its China market strategy.
- Danone product sales to Rockcheck targeted at $30 million AUD over 12 months
- Xenitra’s Australian subsidiary authorised as a supplier to Rockcheck’s conglomerate
- Option to extend sales agreement for an additional three years after first quarter
- Rockcheck is a trillion RMB Chinese conglomerate with a strong health and wellness focus
- Partnership supports Xenitra’s growth and profitability amid recent corporate changes
Strategic Expansion in China
Xenitra Limited (ASX:XEN) has announced a significant expansion of its partnership with the Rockcheck Group, a major Chinese conglomerate. The company has secured a sales agreement to supply Danone products worth approximately $30 million AUD over the next year, starting May 2026. This deal builds on existing sales of over $10 million AUD in the current financial year, underscoring the strength of their collaboration.
The agreement not only targets substantial revenue growth but also includes an option to extend the partnership for an additional three years, contingent on successful sales performance in the first quarter. This provides a clear runway for sustained growth in one of the world’s most competitive consumer markets.
Authorised Supplier Status Unlocks New Channels
Beyond the sales agreement, Xenitra’s Australian trading subsidiary has been formally recognised as an authorised supplier to Rockcheck. This framework agreement is a strategic milestone, enabling Xenitra to directly supply a broad range of fast-moving consumer goods, nutraceuticals, and over-the-counter medicines to Rockcheck’s extensive network.
For Xenitra’s brand partners, this development means enhanced access to a multi-billion dollar B2B sales channel within China, complementing existing ecommerce platforms. The partnership is expected to accelerate market penetration and sales velocity for Western brands entering the Asian market through Xenitra’s ecosystem.
A Foundation for Growth and Profitability
The announcement comes amid a period of corporate restructuring for Xenitra, including board and management changes and cost rebasing. Chairman Dr Anthony Noble highlighted the strategic importance of Rockcheck as a key nutritional products customer and expressed confidence in exceeding sales targets, particularly given Danone’s leadership in the infant formula segment.
With Rockcheck’s diversified portfolio and deep expertise in health and wellness, the partnership aligns well with China’s national priorities and the growing demand for quality nutritional products. Xenitra’s strengthened position in this ecosystem sets the stage for accelerated growth and a clear path towards profitability.
Looking Ahead
As Xenitra leverages this expanded partnership, the company is poised to explore additional product lines and deepen its footprint in the Chinese market. The collaboration with Rockcheck not only validates Xenitra’s multichannel strategy but also signals a broader opportunity to scale its brand acceleration model across Asia.
Bottom Line?
Xenitra’s expanded partnership with Rockcheck is a pivotal step toward scaling its China operations and driving sustainable profitability.
Questions in the middle?
- Will Xenitra successfully meet the first quarter sales targets to trigger the agreement extension?
- What new product lines might be added to the partnership in the coming years?
- How will the authorised supplier status impact Xenitra’s margins and overall revenue mix?
